Company intelligence / Profile preview

Yunnan Vaccine Laboratory

Kunming, Yunnan Province, Chinaresearchgate.net ↗

Ownership: Private
Employees: ~1930
Development stage: Commercial

Overview

Walvax has multiple approved and marketed vaccines including bivalent HPV, pneumococcal conjugate and polysaccharide vaccines, meningococcal vaccines, DTP combination vaccines, and an mRNA COVID‑19 vaccine ("ARCoV") developed with partners. The ARCoV mRNA COVID‑19 vaccine showed good safety and immunogenicity in early trials and is now approved in China and Indonesia. The company continues to expand its pipeline into innovative modalities.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccinemRNA-based drugsConjugated vaccinePolysaccharide vaccineGenetically engineered subunit vaccine
Industry: Biotech

Partnerships

Academy of Military Medical SciencesSuzhou Abogen Biosciences

Beyond the preview

Go deeper on Yunnan Vaccine Laboratory.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yunnan Vaccine Laboratory.

Explore the full profile